lonitoclax
Chronic Lymphocytic Leukemia (CLL)
Key Facts
About Lomond Therapeutics
Lomond Therapeutics is a Boston-based, private, precision hematology company founded in 2021. It is developing a pipeline of small molecule drugs designed to overcome treatment resistance in hematological cancers, with a lead program targeting FLT3/IRAK4 in Acute Myeloid Leukemia (AML). The company's strategy centers on creating 'pan-variant' therapies that inhibit multiple resistance mutations and escape mechanisms simultaneously, aiming to address a critical unmet need in oncology. Leadership includes experienced biotech executives and is backed by venture capital firms like OrbiMed and Teal Ventures.
View full company profileAbout Lomond Therapeutics
Lomond Therapeutics is a Boston-based, private, precision hematology company founded in 2021. It is developing a pipeline of small molecule drugs designed to overcome treatment resistance in hematological cancers, with a lead program targeting FLT3/IRAK4 in Acute Myeloid Leukemia (AML). The company's strategy centers on creating 'pan-variant' therapies that inhibit multiple resistance mutations and escape mechanisms simultaneously, aiming to address a critical unmet need in oncology. Leadership includes experienced biotech executives and is backed by venture capital firms like OrbiMed and Teal Ventures.
View full company profileTherapeutic Areas
Other Chronic Lymphocytic Leukemia (CLL) Drugs
| Drug | Company | Phase |
|---|---|---|
| Ublituximab | TG Therapeutics | Phase 3 |